International cancer seminars: a focus on esophageal squamous cell carcinoma


1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda Maryland, USA; Sections of 2Environment and Radiation; 3Genetics, 4Cancer Surveillance, International Agency for Research on Cancer, Lyon, France; 5Department of Biochemistry, University of Kashmir, Hazratbal, Srinagar, Jammu and Kashmir, India; 6MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; 7Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA; 8University of North Carolina Project-Malawi, Lilongwe, Malawi; 9Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran; 10Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, Maryland, USA; 11Department of Medical and Molecular Genetics, Kings College London; 12Sydney Brenner Institute for Molecular Bioscience, University of Witwatersrand, Johannesburg, South Africa; 13School of Public Health, Massachusetts Institute of Technology, Boston, MA, USA; 14Tenwek Hospital, Bomet, Kenya; 15Kilimanjaro Christian Medical Centre, Moshi, Tanzania; 16Department of Etiology and Carcinogenesis & Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; 17Molecular Carcinogenesis Program, Institute Nacional de Cancer, Sao Paulo, Brazil; 18National Cancer Institute, Center for Global Health, National Institutes of Health, Bethesda, Maryland, USA; 19School of Public Health, University of Sydney, New South Wales, Australia; 20School of Public Health & Community Medicine, University of New South Wales, Sydney, Australia; 21Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA; 22Director’s office, International Agency for Research on Cancer, Lyon, France

*Correspondence to: Dr Stephen J. Chanock, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI Shady Grove, #7E412, Bethesda, MD 20892-9776, USA. Tel: +1-240-276-7150; E-mail: chanocks@mail.nih.gov

The International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) have initiated a series of cancer-focused seminars [Scelo G, Hofmann JN, Banks RE et al. International cancer seminars: a focus on kidney cancer. Ann Oncol 2016; 27(8): 1382–1385]. In this, the second seminar, IARC and NCI convened a workshop in order to examine the state of the current science on esophageal squamous cell carcinoma etiology, genetics, early detection, treatment, and palliation, was reviewed to identify the most critical open research questions. The results of these discussions were summarized by formulating a series of ‘difficult questions’, which should inform and prioritize future research efforts.

Key words: esophageal squamous cell carcinoma (ESCC), epidemiology, genomics, early detection, clinical research

Introduction

Esophageal cancer is the eighth most common cancer worldwide, and the sixth most common cause of cancer death [1,2]. It has two dominant histologic types: esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC). In 2012, there were an estimated 398,000 new ESCC cases worldwide, representing 87% of all esophageal cancer [3].

The geographic distribution of ESCC is one of the most uneven of all cancers, with high incidence regions stretching across Asia from China to Iran, from eastern to southern Africa, and in parts of southern South America (Figure 1) [3]. Recognized ESCC hotspots, past and present, exist within sharply defined regions including Linxian China, Golestan Province in Iran, Western Kenya south to Malawi, the Eastern Cape province of South Africa, Calvados in France, Southern Brazil and Uruguay [3]. The burden of ESCC is particularly striking in these high incidence areas: in Linxian county, China, esophageal cancer is the most common cancer in both men and women, in South Africa it is the most common cancer in men, second most common in women (Figure 2) [4].

ESCC is also marked by striking etiologic heterogeneity. In low and medium incidence populations ESCC is largely attributable
to smoking and alcohol and incidence rates are three to four times higher in men than in women. This was also true of historically highly affected areas such as Calvados and France [5]. In the USA, population attributable risks as high as 89% have been reported for ESCC, based on smoking habits and consumption of alcohol, fruit, and vegetables [6], with similar attributable risks reported for esophageal cancer death from the UK (89%) [7], Nordic countries (89%) [8], and France (74%) [9]. In contrast, tobacco use and alcohol consumption are less common and less intensely practiced and play a lesser role in the etiology of ESCC in high incidence areas in Asia [10]. Similar studies in China have estimated that 46% of esophageal cancer deaths are attributable to the combined effects of smoking [11, 12], drinking alcohol, and low fruit and vegetable intake [13]. Most high incidence regions also have male:female ratios that approach 1:1 [14].

ESCC research is made particularly compelling because of the rapidly fatal course of the cancer, the late stage presentation juxtaposed with the important contribution of modifiable risk factors. Five-year survival rates for esophageal cancer are 20% in the USA [15], 21% in China [16], 12% in Europe [17], and <5% in the lower resource settings [18, 19] suggesting that primary and secondary prevention are key to reducing mortality from this disease.

ESCC in Europe and in the US are predominantly driven by alcohol and tobacco, which have a strong synergistic effect on ESCC risk [5]. The Calvados region of Northern France exhibited exceptionally high rates in the past, although these are now moderate. The cause for the past high incidence rates is largely due to the heavy consumption of a particular type of brandy, that was often distilled at home and drunk hot [20]. The existence of high incidence regions in Asia and Africa [21] are more difficult to explain, since many suspected risk factors are also prevalent elsewhere, suggesting the presence of locally operating risk factors yet to be identified and/or the likely co-occurrence of multiple interacting factors. Nonetheless, a number of risk factors consistently associated with ESCC in high incidence regions have been identified, many of which are often present in the lower socioeconomic groups most affected by the disease.

In addition to tobacco use and alcohol consumption, the International Agency for Research on Cancer (IARC) monograph series have identified several exposures as causally linked to ESCC including acetaldehyde from alcoholic beverages [22], betel quid with or without tobacco [23], and X- and gamma-radiation [23].
The consumption of hot foods and beverages has been suggested to be an etiologic factor for ESCC across diverse populations in China, Iran, Brazil, and Tanzania [24–27]. Hot beverages were recently classified as probably carcinogenic to the esophagus in the IARC Monograph Series [28]. Mate is a herbal infusion, that is popular in southern Brazil, Uruguay, Paraguay, and Argentina, and traditionally it is drunk very hot (>65°C). Mate consumed ‘hot’ or ‘very hot’ [26] has been associated with an increased risk of ESCC [29]. Elevated risk of ESCC has also been linked to the consumption of very hot tea and other beverages [24, 25, 27, 28], however, a paucity of published data led the IARC Working Group to conclude that there is limited evidence in humans for the carcinogenicity of drinking very hot beverages, and inadequate evidence in humans to evaluate the carcinogenicity of drinking maté that is not very hot.

Poor diet has been suggested to play a role in ESCC risk, and studies have investigated the effects of specific foods, nutrients, or dietary patterns [30–32]. The excess risk associated with poor diet may stem from specific nutritional deficiencies, rather than poor nutrition in general. One micronutrient which has been studied with respect to ESCC is selenium. Regions with both selenium deficient soil or crops and high incidence of ESCC have been identified across the world, including the Taihang mountains in China and parts of east Africa [33]. Several intervention and observational studies have shown that selenium deficiency may be a risk factor for upper gastrointestinal cancers in Linxian, in the Taihang mountains [34–36], but this has not been formally tested in other regions of the world with high incidence of ESCC.

Another apparent risk factor for ESCC is polycyclic aromatic hydrocarbon (PAH) exposure. PAHs are environmental carcinogens produced during incomplete combustion of organic material, including tobacco, coal, and wood. High PAH exposure has been documented in urine samples from healthy subjects in Linxian, China [37], Golestan, Iran [38], and Rio Grande do Sul, Brazil [39], as well as in non-tumor esophageal tissue from ESCC cases in Golestan, Iran [40]. High PAH content has also been detected in staple foods in Linxian [41] and commercially processed maté leaves and beverages from Rio Grande do Sul [42, 43]. Such findings form the basis of a compelling hypothesis that PAHs from both tobacco and non-tobacco sources contribute to the pathogenesis of ESCC. Although exposure to PAHs in these regions is high and these chemicals are known to be carcinogenic, definitive association studies for ESCC have not been completed.

We note that several recent studies [37, 44–48] strongly suggest that Human Papilloma Virus plays little if any role in ESCC etiology, so that anti-HPV vaccines will not play a role in ESCC prevention.

Figure 2. Cancer incidence in five continents, Vol. X: Registries with age-standardized incidence in either gender of at least 15 per 100,000.
Other less studied but possible risk factors in high incidence populations include poor oral hygiene/tooth loss [49–53], prolonged close contact with ruminant animals [54–56], and the oral microbiome [57, 58].

Challenges outstanding

**The next generation of etiologic studies.** ESCC risk factors are likely acting in combination with each other, or with some as yet unidentified factor(s). Existing cohorts in Linxian, China [10] and Golestan, Iran [59] provide important resources for studying ESCC in distinct populations. However, the concentration of ESCC in low-resource areas, such as eastern and southern Africa, precludes the rapid implementation of multiple large cohort studies. In the absence of cohorts, multiple case–control studies of ESCC etiology are needed in understudied populations, particularly in east Africa. These studies must ensure high quality data collection and should use harmonized, but locally tailored, data and biospecimen collection protocols. Putative risk factors that have suggestive, but not conclusive, evidence of their ESCC risk include: hot beverage/food consumption, animal exposure, oral health, opium [60], pickled foods [61], salt tea [62], fermented milk [63], and nitroamines. Further studies to identify exposure sources and routes are needed, to enable translation to primary prevention of ESCC in high incidence regions. Definitive prospective (cohort) studies using biomarkers of exposure (such as PAH metabolites in urine) are needed. Lastly, comparing and contrasting the population attributable risks for identified risk factors in high and low incidence areas would be a worthy addition to the ESCC literature.

**Translating etiologic data into public health policy.** Tobacco on its own, or in combination with alcohol, continue to have an important role in esophageal cancer in many regions, and while they cannot explain the high incidence rates that are observed in Asia, they do present opportunities for prevention. Currently, many parts of Africa have low tobacco use rates and limiting the tobacco epidemic in this region will continue to be a public health priority. Evidence for the consumption of hot beverages increasing risk of ESCC is mounting and, in high risk areas, public health campaigns targeting the consumption of very hot beverages should be considered.

**Genetics and somatic studies**

There is strong evidence for the role of genetics in the etiology of ESCC. Numerous previous studies have consistently found strong increased risk of ESCC in persons who reported a positive family history of ESCC [10, 64–68]. Estimates of cancer heritability based on genome-wide association studies (GWAS) showed that ESCC had the highest heritability of all 13 cancers evaluated [68]. In addition, a familial esophageal cancer syndrome, tylosis, inherited as an autosomal dominant trait, has been reported and associated with mutations in **RHBDF2** [69].

Polymorphisms in **ADH1B**, **ADH7**, and **ALDH2** are known to alter ethanol metabolism, and have been linked to altered risk of ESCC among alcohol consumers in both Asian and European populations [70, 71]. In other hypothesis-driven single nucleotide polymorphism (SNP) studies, a rare **BRCA2** variant was shown to have a large association (between threefold and sixfold) in separate European and Iranian populations [72, 73]. A number of genome wide association studies (GWAS) of ESCC have been undertaken to date in China [74, 75] and Europe [76]. A comprehensive joint analysis of the Chinese studies, which included 5337 ESCC cases and 5787 controls, with a replication study which included 9654 cases and 10 058 controls [77] confirmed a number of loci, identified two new susceptibility loci, and found a new locus in the **HLA class II** region that was limited to the population in the high-incidence Taihang Mountain region in China. Cumulatively, ESCC GWAS in Asians have identified a total of 16 risk loci to date, including 14 with main effects and two others evident only because of an interaction with alcohol use. Five of these GWAS loci have also been tested for ESCC association in African populations, and **RUNX1** and **PLCE1** showed some limited evidence of association [78].

Many of the early somatic mutations studies of ESCC focused on **TP53** [79, 80]. The distinct etiologic heterogeneity of ESCC may be reflected in the **TP53** mutation patterns observed in tumors from different high and low ESCC incidence regions, though this does not always appear predictable; that is, the proportion of tumors containing **TP53** mutations is not necessarily highest in high ESCC incidence areas [81–84]. With the advent of Next-Generation Sequencing, a more complete characterization of common mutations is already underway [85–92].

Genomic studies of ESCC tumors have also reported promising candidate DNA methylation markers for early detection, and tumor prognosis [93], however, studies have been notably limited in their size [94–96]. Whole exome studies of ESCC have identified mutation signatures similar to those seen in other squamous cancers and distinct from esophageal adenocarcinomas [48, 89, 97]. A recent report from Malawi, the first of its kind from Africa, identified a subset of tumors where **TP53** mutations were rare, and a subset of tumors with an unknown mutation signature, consistent with an unidentified environmental exposure [48], but the data remain too sparse to draw strong conclusions.

Challenges outstanding

**Ethnically diverse and adequately powered GWAS and tumor sequencing studies.** Large scale GWAS of ESCC beyond subjects of Chinese ethnicity are needed, particularly from eastern and south-eastern Africa, north-eastern Iran, South America and central Asia. Large scale tumor sequencing studies could also help to highlight mutation signatures [98] linked to underlying causes, and may help to identify to what extent risk factors are common across high risk areas. Both of these projects will require large scale, high quality bio-repositories that combine lifestyle data, biologic sample collection, appropriate ethical and consent oversight, and bio-repository infrastructure support. Cancer Research UK recently funded a large mutation signature study that aims to include 1000 ESCC from low and high incidence populations, which will shed new light on the potential similarities and differences in etiologic agents across the globe.
Molecular data from Africa are underrepresented in the literature. Particular focus and support should be given to genetic and genomic studies originating in Africa, which have been notably limited to date and have often been small in size and underpowered considering the lower linkage disequilibrium patterns observed in African populations. The significantly younger age profile of African ESCC cases may make genetic and genomic studies there particularly relevant.

**Early detection, treatment, and care**

The pathogenesis of ESCC has been well characterized, including identification of a recognizable precursor lesion, esophageal squamous dysplasia (ESD), which affords the possibility of intervention to detect and manage precursor lesions and prevent tumor development. In one region of exceptionally high ESCC incidence in China, endoscopic screening of asymptomatic adults with use of Lugol’s iodine to detect ESD, and endoscopic mucosal resection and/or ablation to treat high-grade ESD has proven effective in reducing both ESCC incidence and mortality [99].

However, mass endoscopic screening to detect and remove ESD would present a substantial challenge even in a high-resource environment and is not tenable in most high incidence regions. A robust risk stratification system might substantially increase efficiency, but efforts to date have not been promising [100]. Previous studies have explored the use of esophageal balloon, or sponge cytology, as a less invasive primary screening test for detecting dysplasia and carcinoma among asymptomatic individuals [101, 102], but the accuracy of detection using routine cytologic readings was too low to be clinically useful. Recently sponge cytology in combination with molecular markers has proven effective for detecting Barrett’s esophagus [103, 104] and this may prove useful for primary detection of ESD as well.

Early detection of ESCC is critical because disease prognosis and management are determined by the stage at which ESCC is detected. The advent of endoscopic treatment (radiofrequency ablation, cryotherapy, endoscopic mucosal resection, submucosal dissection) for high-grade ESD, or early ESCC in China, Iran and Kenya offers tangible potential for early detection and cancer prevention in high incidence regions. For palliative care, the availability of self-expanding metal stents could dramatically improve the quality of life for patients presenting with late stage tumors. Lack of fluoroscopy devices in many areas has necessitated the development of stenting techniques that do not require fluoroscopy and are safe and reproducible [19].

**Challenges outstanding**

**Optimizing population-based screening strategies.** In China, where population-based endoscopic screening is already underway in high ESCC incidence areas, there is a need to optimize the screening strategy (which age groups to include, optimal screening intervals, appropriate follow-up methods, etc.).

**Development of a primary non-endoscopic screening test and risk stratification models for ESD.** Development of accurate, low cost methods for primary screening for high-grade ESD should be prioritized. Accurate and comprehensive knowledge of local risk factors could also help build locally effective risk prediction models.

**Priorities for the development of early detection markers.** Future field studies of ESCC should incorporate collecting appropriate tissue samples and blood. Developing biorepositories of tumor, adjacent normal tissue, precursor lesions (low- and high-grade ESD), and blood with linked questionnaire/demographic data, will provide a resource for development of early detection markers. Molecular profiling of ESCC tumors has shown promise in identifying markers for early detection and should be continued and expanded. Comparative studies of molecular profiles from tumors and dysplastic lesions originating in different low- and high-incidence areas may be particularly insightful.

**Knowledge transfer for physicians in high incidence regions.** The success of large scale screening trials in China also creates a valuable training resource for endoscopists and surgeons all over the world. Short-term training programs in high-incidence areas of China could enable physicians from other high risk regions to expand their capacity, whether in the use of Lugol’s iodine for lesion detection, endoscopic therapy of high risk lesions, esophagectomy, for operable invasive tumors, and/or in esophageal stent placement for palliation.

**Access to palliative care in Africa.** In many places nearly all patients with ESCC present with advanced obstructing lesions that are only amenable to palliation, which in low-resource settings is generally limited to the placement of stents. Producing affordable stents and providing resources and training to allow physicians to offer stent palliation to ESCC patients in low resource settings must be prioritized given the clear evidence that stent palliation can be very valuable to patients [19].

**Conclusion**

Decades of study in ESCC high incidence regions of China [10, 34, 36, 49, 50, 102, 105] and a growing body of evidence from Iran [25, 38, 40, 46, 51, 55, 59, 100, 106–108] and recent studies in Africa [21, 27, 48, 109–111] have provided insights on the epidemiology, etiology, early detection, and management of ESCC. Programs in high incidence regions in China and Iran are currently informing new field studies in Africa and elsewhere, and offer opportunities for powerful pooled epidemiologic studies, real-time data sharing, and knowledge transfer. Definitive ESCC risk factors should be tested in primary prevention studies. Future studies should work to describe unknown triggers working with highly prevalent regional exposures. Additional genetic and genomic studies are needed, particularly in Africa, which is not well represented in the current genomic literature. Such studies could provide data for risk stratification and contribute to our understanding of etiologic heterogeneity. Development of a clinically useful non-endoscopic primary screening test should be a high priority, because it could dramatically impact the ESCC burden in high incidence regions. Increasing the availability of affordable stents could significantly...
improve the quality of life of those patients with late-stage tumors. Progress to date means there is now great promise for ESCC cancer prevention, early detection, and treatment.

**Difficult research questions that should be prioritized**

1. What explains the distinctive geographic pattern of high ESCC incidence in regions of Asia, Africa, and South America. Is there a common underlying cause or combination of causes?
2. Tobacco and alcohol are important in some areas (e.g., Europe and the USA), but appear to play a lesser role in Asia. What is the role of these risk factors, which are amenable to preventive interventions, in the high risk regions of Africa?
3. Can we produce definitive evidence that high temperature foods and beverages modulate ESCC risk in different populations, and should we design public health interventions to reduce risk from this exposure?
4. PAH exposure is common to each of the high incidence populations in Asia, Africa, and South America, but can we complete definitive association studies using biomarkers for this exposure?
5. Are dietary/mineral deficiencies a risk factor for ESCC in the high risk regions of China and elsewhere?
6. Is it possible to develop better animal models of ESD, to improve experimental testing of proposed ESCC etiologic mechanisms?
7. Is it possible to develop non-endoscopic screening tools, using one or more molecular markers, to identify high grade dysplasia and risk stratify asymptomatic adults in high incidence populations?
8. Can we identify the appropriate ages, and follow-up intervals, for ongoing endoscopic screening programs?
9. What is the role of endoscopic therapy in the treatment of precursor and early invasive ESCC lesions, and which can be carried out safely and effectively outside of specialized centers?
10. Are stents that best choice for palliative care and how can reasonably priced palliative care be delivered to patients in low-resource areas such as Africa?

**Funding**

This seminar was funded jointly by the International Agency for Research on Cancer (IARC) and the Division of Cancer Epidemiology and Genetics (DCEG) of the US National Cancer Institute Intramural Research Program (no grant number applicable).

**Disclosure**

The authors have declared no conflicts of interest.


80. Bouaoun LSD, Ardin M, Hollstein M et al.
82. Rossini A, de Almeida Simao T, Marques CB et al.
83. Putz A, Hartmann AA, Fontes PR et al.
84. Rohe MJ, Liu SF, Dawsey SM et al.
85. Wei WQ, Chen ZF, Borok M et al.
86. Ross-Innes CS, Debiram-Beecham I, O’Donovan M et al.
88. Nasrollahzadeh D, Kamangar F, Aghcheli K et al.
89. Qian H, Niu XY, Chen Y et al.
90. Qin HD, Liao XY, Chen YB et al.
92. Chen H, Huang X et al.
93. Tong Y, Zhao H et al.
95. Li X, Zhou F, Jiang C et al.
97. Song Y, Li L, Ou Y et al.
98. Bignell GR, Greenman CD, Davies H et al.
99. Wei WQ, Chen ZF, Ye YT et al.
100. Pan QJ, Roth MJ, Guo HQ et al.
101. Qian H, Niu XY, Chen Y et al.
103. Islam F, Kamangar F, Aghcheli K et al.
105. Wei WQ, Chen ZF, Borok M et al.